Daiichi Sankyo's stock has dropped 25% since my last update due to disappointing clinical data from Dato-DXd studies, but upcoming read-outs in 2025 could drive a meaningful rebound. Dato-DXd ...
TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company ... of advanced solid tumors including non-small cell lung, breast, urothelial, ovarian, biliary tract ...
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody ...
Daiichi Sankyo has been particularly active in this field, and the company’s collaborations including the one with AstraZeneca, have led to the development of successful drugs like Enhertu ...
Daiichi Sankyo ... using Daiichi Sankyo’s proprietary DXd ADC technology. DS-3939 is currently being evaluated in a phase 1/2 clinical trial in patients with several types of advanced solid tumours ...
“Treating advanced EGFR-mutated non-small cell lung cancer ... Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU ® in March 2019 ...
Daiichi Sankyo and AstraZeneca’s (AZN ... or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who have received prior systemic therapies, including an EGFR-directed ...
Daiichi Sankyo.“If approved, datopotamab deruxtecan could become the first TROP2 directed antibody drug conjugate for lung cancer, providing a promising option for patients.” “Acquired ...
11 There is currently no TROP2 directed ADC approved for the treatment of lung cancer ... About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of seven ADCs in ...
non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug ...
Daiichi Sankyo (OTCPK:DSKYF ... patients using the drug should be closely monitored for signs of interstitial lung disease. Datroway is the first TROP-2 directed drug to be approved in Japan ...